Halozyme and Celanese Earnings Misses Signal Margin Pressure Across Sectors
A wave of earnings reports from Halozyme Therapeutics, Celanese, and OneSpaWorld has revealed significant bottom-line misses, highlighting growing cost pressures and demand volatility. While Halozyme managed a revenue beat, its massive EPS shortfall points to substantial operational or one-time headwinds that are rattling investor confidence.